scholarly journals Determination of Glycated Apolipoprotein B in Serum by a Combination of Affinity Chromatography and Immunonephelometry

1994 ◽  
Vol 31 (6) ◽  
pp. 544-549 ◽  
Author(s):  
M Panteghini ◽  
R Bonora ◽  
F Pagani
Keyword(s):  
Affinity Chromatography ◽  
Apolipoprotein B ◽  
Diabetic Patients ◽  
Apo B ◽  
Coefficients Of Variation ◽  
Free Glucose ◽  
The Mean

We have developed and optimized a procedure for the quantitation of non-enzymatically glycated apolipoprotein B (apo B). Glycated and non-glycated apo B were separated from serum using m-aminophenylboronate affinity chromatography, determined by immunophelometry and the percentage of glycated apo B was calculated. The measuring range of the assay was 2·9–185 mg/dL apo B. The within- and between-run coefficients of variation were <7·4% and 14·6%, respectively, and recovery was >98%. Free glucose in serum did not affect the results at concentrations below 25 mmol/L. In 45 non-diabetic subjects the mean concentration of glycated apo B was 4.3% (SD 1%). In type 1 ( n = 17) and Type 2 ( n = 60) diabetic patients the mean glycated apo B concentrations were 5·3% (SD 0·7%) and 5·9% (SD 1·1%), respectively, significantly higher than in controls ( P<0·001).

Comparison the effects of aqueous and ethanolic extracts of Rheum ribes on insulin resistance and apolipoprotein AI (ApoA1), apolipoprotein B (ApoB) and Apo B to ApoA1 ratio in patients with type 2 diabetes mellitus: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial

2020 ◽  
Author(s):  
Atieh Ghafouri ◽  
Sahar Jafari Karegar ◽  
Ghazaleh Hajiluian ◽  
Sharieh Hosseini ◽  
Shahrzad Shidfar ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Apolipoprotein B ◽  
Serum Levels ◽  
Diabetic Patients ◽  
Model Assessment ◽  
Apo B

Abstract Background: This study was conducted to determine the effect of Rheum ribes supplementation on glycemic indices and apolipoproteins in patients with type 2 diabetes mellitus (DMT2).Methods: In this randomized controlled trial, sixty type 2 diabetic patients, aged 30-60 years with body mass index (BMI) of 20-30 kg/m 2 , and hemoglobin A1c (HbA1c) of 6-8% were included. The patients were randomly assigned to receive 450 mg of Rheum ribes aqueous extract (AG), 450 mg of Rheum ribes ethanolic extract (EG) or placebo (PG), three times daily for 6 weeks. Then glucose, the homeostatic model assessment (HOMA-IR and HOMA-B) and apolipoprotein A-I (ApoA1) and apolipoprotein B (ApoB) were measured.Results: According to these findings, in the AG and EG intervention groups, we observed a significant reduction in serum levels of insulin (P=0.003 and P=0.001, respectively), HOMA-IR (P=0.01 and P=0.001, respectively) and HOMA-B (P=0.002 and P=0.001, respectively) indices, without no significant changes in glucose. There was also a significant reduction in serum levels of ApoB (P=0.006 and P=0.03, respectively) and ApoB/ApoA1 ratio (P=0.016 and P=0.04, respectively) in both AG and EG. Intervention in both AG and EG had increasing effects on ApoA1 (P=0.08 and P=0.05, respectively). None of these variables had a significant change in PG. At the end of study, there were significant differences in insulin (P=0.04), HOMA-IR (P=0.03), HOMA-B (P=0.01), ApoB (P=0.02), and ApoB/ApoA1 (P=0.03) ratio among groups.Conclusions: Rheum ribes intake may have favorable effects on insulin resistance and apolipoproteins in diabetic patients.Trial registration: The study was recorded in Iranian Registry of Clinical Trials under the registration number of IRCT201410142709N31 (Registration date: 2014-12-11, https://en.irct.ir/trial/2543 ).

scholarly journals Computed Tomography Analysis of the Ethmoid Roof: A Region at Risk in Endoscopic Sinus Injury

2019 ◽  
Vol 19 (2) ◽  
pp. 108-115
Author(s):  
Pra Urusopone
Keyword(s):  
Computed Tomography ◽  
Facial Bones ◽  
Significant Difference ◽  
The Mean ◽  
Type 3 ◽  
Tomography Analysis

Objective: To determine the olfactory fossa depth according to the Keros classification and determine the incidence of asymmetry in height and configuration of the ethmoid roof. Materials and Methods: Retrospective analysis of 75 coronal computed tomography studies of paranasal sinuses and facial bones were performed. Measurement of the depth of the lateral lamella, classification of the depth according to Keros type and determination of the asymmetries in the ethmoid roof depth and configuration were done. Results: The mean height of the lateral lamella cribiform plate (LLCP) was 2.15+1.29 mm. The cases were classified as 87.33% Keros type1 and 12.67 % as Keros type 2. No Keros type 3 was found .There was asymmetry in the LLCP height of 33.33% of cases and a configuration asymmetry in 8% of the cases. No significant difference between the mean height and distribution of Keros type between gender and laterality were also found. Conclusion: As regards the olfactory fossa depth, the Keros type 1 was most frequently found. Asymmetry in the depth and configuration were detected in 33.33 and 8% respectively. Risk of inadvertent intracranial entry through the lateral lamella among Thai may be lower than other studies with majority of cases classified as Keros type 2 or 3.

scholarly journals Diabetic Retinopathy and Central Corneal Thickness

2019 ◽  
Vol 3 (3) ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Retinopathy ◽  
Central Corneal Thickness ◽  
Corneal Thickness ◽  
Diabetic Patients ◽  
Type I ◽  
Type Ii ◽  
The Mean

Background: Diabetes mellitus (DM) is a metabolic disease that can lead to many ocular complications such as increased Central Corneal Thickness (CCT), cataracts, and diabetic retinopathy. The aim of this study was to compare the CCT between subjects with type I and type II diabetes. Method: This was a retrospective study which included subjects with diabetes (with and without Diabetic Retinopathy (DR)) aged between 18 to 80 years old. The data collected were type and duration of diabetes mellitus, diabetes treatment, glycated hemoglobin level, visual acuity, CCT, and intra ocular pressure. Subjects were divided into subgroup (with and without DR). Statistical program (SPSS) was used to compare the central corneal thickness between the groups. Result: A total of 205 subjects with type I (n=100) and type II (n=105) diabetes were included in this study. In type 1 DM, the mean CCT was 547.06±27.3 microns in patients with diabetic retinopathy (DR) and 533.85±26.8 microns in patients without DR. In type 2 DM, the mean CCT was 542.85±39.3 microns in patients with DR and 532.44±27.4 microns in patients without DR. The CCT in type 1 diabetic patients was higher in both groups (with and without DR) than the CCT in type 2 diabetic patients in both groups (with and without DR). However, this was not statistically significant. Conclusion: The type of diabetes mellitus did not affect CCT. The presence of diabetic retinopathy in either type I or type II diabetes mellitus can affect the measurements of CCT.

scholarly journals Assessment of Thyroid Profile of Type 1 and Type 2 Diabetes Mellitus Patients and Patients with Diabetic Complications

2020 ◽  
Vol 6 ◽  
pp. 1
Author(s):  
Friday K Iweka ◽  
Godwin RA Okogun ◽  
Ebenezer O Dic-Ijiewere ◽  
Lawrence F Dada ◽  
Iredia K Akhuemokhan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Diabetic Patients ◽  
Hypertensive Patients ◽  
Control Subjects ◽  
The Mean ◽  
Thyroid Profile

This study was undertaken to assess the thyroid profile of diabetes mellitus (DM) patients and patients with some associated complications in the Edo state, Nigeria. Blood samples from 267 subjects, consisting of 164 diabetic patients (24 type 1 DM and 140 type 2 DM) and 103 nondiabetic apparently healthy individuals (as controls), were analyzed. The thyroid stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4) levels were determined using the enzyme linked immunosorbent assay (ELISA). From the result obtained, the T3 level was found significantly (p < 0.05) higher in diabetic-nephropathy (D-NEPHR) patients than the control subjects, while the TSH and T4 levels of D-NEPHR were insignificantly (p > 0.05) higher than those of the control group. The mean TSH level was significantly (p < 0.05) lower in diabetic hypertensive patients when compared with the control group, while the plasma T3 level was significantly (p < 0.05) higher in diabetic hypertensive patients when compared with the control group. There was no significant difference (p > 0.05) in the mean value of T4 of diabetic hypertensive patients when compared with the control subjects. The mean plasma T3 and T4 were significantly (p < 0.05) higher in diabetic neuropathy (D-NEUR) patients than those of control subjects. There were no significant (p > 0.05) differences in the mean plasma TSH level of D-NEUR patients when compared with those of control subjects. The mean plasma T3and T4 levels of diabetic patients with coronary heart disease (DM-CHD) were significantly (p < 0.05) higher than those of control subjects while the mean plasma TSH level of DM-CHD was significantly (p < 0.05) lower than that of control subjects. No significant (p > 0.05) difference in the mean plasma TSH, T4, and T3 levels of diabetic retinopathy subjects when compared with those of control subjects was obtained.

scholarly journals Assessment of plasma insulin, c-peptide, and blood pressure parameters of type 1 and type 2 diabetes mellitus and diabetic complications

2020 ◽  
Vol 10 (1) ◽  
pp. 1635-1638
Author(s):  
Friday K. Iweka ◽  
Godwin R.A. Okogun ◽  
Ebenezer O. Dic-Ijiewere ◽  
Lawrence F. Dada ◽  
Iredia K. Akhuemokhan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Plasma Glucose ◽  
Diabetic Patients ◽  
C Peptide ◽  
Peptide Level ◽  
The Mean ◽  
Artery Disease

Background: Regardless of the type of diabetes mellitus, there is always a Beta-cell dysfunction leading to absolute insulin deficiency in type 1 diabetes mellitus or associated with insulin resistance in case of type 2 diabetes mellitus. Materials and Methods: A total of 267 subjects consisting of 164 diabetic patients and 103 non-diabetic apparently healthy individuals were analysed. The plasma insulin and c-peptides levels were determined using enzyme link immunosorbent assay, while plasma glucose level was determined using standard spectrophotometric method. Results: The biochemical results showed that the mean plasma glucose of Type 1 diabetes (213.65±20.35) and Type 2 diabetes (218.78+7.85) were significantly (P<0.05) higher than that of non-diabetic control (81.88±17.22) mg/dl; the mean plasma glucose and the systolic reading of the Diabetes Mellitus with Nephropathy, hypertension, coronary artery disease, neuropathy, and retinopathy patients were significantly (p<0.05) higher than the control subjects. Among diabetic hypertensive patients mean insulin and c-peptide levels were significantly (p<0.05) lower, while the mean insulin level was insignificantly (p>0.05) lower in diabetic patients with neuropathy or coronary artery disease. No significant (p>0.05) differences was observed in the mean plasma c-peptide level, and diastolic reading of diabetic patient with neuropathy. There were no significant (p>0.05) differences in the mean plasma c-peptide level, systolic and diastolic readings of Diabetic patients with coronary heart disease or retinopathy. Conclusion: There were significant differences in the blood pressure parameters in both the diabetes mellitus and diabetic complications in this study.  

scholarly journals Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Peter Bramlage ◽  
Stefanie Lanzinger ◽  
Sascha R. Tittel ◽  
Eva Hess ◽  
Simon Fahrner ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Clinical Practice ◽  
Kidney Disease ◽  
Analysis Data ◽  
Disease Diagnosis ◽  
Diabetic Patients ◽  
European Society Of Cardiology

Abstract Background Recent European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) guidelines provide recommendations for detecting and treating chronic kidney disease (CKD) in diabetic patients. We compared clinical practice with guidelines to determine areas for improvement. Methods German database analysis of 675,628 patients with type 1 or type 2 diabetes, with 134,395 included in this analysis. Data were compared with ESC/EASD recommendations. Results This analysis included 17,649 and 116,747 patients with type 1 and type 2 diabetes, respectively. The analysis showed that 44.1 and 49.1 % patients with type 1 and type 2 diabetes, respectively, were annually screened for CKD. Despite anti-diabetic treatment, only 27.2 % patients with type 1 and 43.5 % patients with type 2 achieved a target HbA1c of < 7.0 %. Use of sodium-glucose transport protein 2 inhibitors (1.5 % type 1/8.7 % type 2 diabetes) and glucagon-like peptide-1 receptor agonists (0.6 % type 1/5.2 % type 2 diabetes) was limited. Hypertension was controlled according to guidelines in 41.1 and 67.7 % patients aged 18–65 years with type 1 and 2 diabetes, respectively, (62.4 vs. 68.4 % in patients > 65 years). Renin angiotensin aldosterone inhibitors were used in 24.0 and 40.9 % patients with type 1 diabetes (micro- vs. macroalbuminuria) and 39.9 and 47.7 %, respectively, in type 2 diabetes. Conclusions Data indicate there is room for improvement in caring for diabetic patients with respect to renal disease diagnosis and treatment. While specific and potentially clinically justified reasons for non-compliance exist, the data may serve well for a critical appraisal of clinical practice decisions.

The effect of insulin pump therapy in retinal vasculature in type 1 diabetic patients

2021 ◽  
pp. 112067212199057
Author(s):  
Tomás de Oliveira Loureiro ◽  
João Nobre Cardoso ◽  
Carlos Diogo Pinheiro Lima Lopes ◽  
Ana Rita Carreira ◽  
Sandra Rodrigues-Barros ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Metabolic Control ◽  
Insulin Pump Therapy ◽  
Vascular Density ◽  
Diabetic Patients ◽  
Retinal Vasculature ◽  
Increased Risk ◽  
The Mean ◽  
Type 1 Diabetic Patients

Background/objectives: Continuous subcutaneous insulin infusion (CSII) is a treatment for type 1 diabetes that improves metabolic control and reduces micro and macrovascular complications. The aim of this study was to compare the effect of CSII versus traditional multiple daily injections (MDI) therapy on retinal vasculature. Methods: We performed a prospective study with type 1 diabetic patients with no prior history of ocular pathology other than mild diabetic retinopathy. The patients were divided into two groups according to their therapeutic modality (CSII vs MDI). The retinal nerve fiber layers thickness and vascular densities were compared between groups in both macula and optic disc. The correlations between vascular density and clinical features were also determined. Statistical significance was defined as p < 0.05. Results: The study included 52 eyes, 28 in the insulin CSII group. The mean age was 36.66 ± 12.97 years, with no difference between groups ( p = 0.49). The mean glycated hemoglobin (HbA1c) was found to be lower in the CSII group (7.1% ± 0.7 vs 7.5% ± 0.7 p < 0.01). The parafoveal vascular density was found to be higher in the CSII group (42.5% ± 0.4 vs 37.7% ± 0.6, p < 0.01). We found an inverse correlation between HbA1c value and parafoveal vascular densities ( p < 0.01, r = −0.50). Conclusion: We found that CSII provided better metabolic control than MDI and this seemed to result in higher parafoveal vascular density. As lower vascular density is associated with an increased risk of diabetic retinopathy, these results suggest that CSII could be the safest therapeutic option to prevent retinopathy.

Sign in / Sign up

Export Citation Format

Share Document